Showing 1 - 20 results of 301 for search '"Food and Drug Administration"', query time: 0.13s Refine Results
  1. 1

    Should the Food and Drug Administration Limit Placebo-Controlled Trials? by Max Goodman, Connor Pedersen

    Published 2022-07-01
    Subjects: “…Food and Drug Administration…”
    Get full text
    Article
  2. 2

    A Machine Learning Algorithm to Predict Medical Device Recall by the Food and Drug Administration by Victor Barbosa Slivinskis, Isabela Agi Maluli, Joshua Seth Broder

    Published 2024-11-01
    “…While the United States Food and Drug Administration (FDA) employs an adverse event reporting program (MedWatch) and database (MAUDE), other data sources and methods might have utility to identify potentially dangerous medical devices. …”
    Get full text
    Article
  3. 3

    Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database by Bojing Wang, Shu Huang, Shu Huang, Shiqi Li, Yaqi Deng, Ziyan Li, Yizhou Wang, Xiaomin Shi, Wei Zhang, Lei Shi, Xiaohong Wang, Xiaowei Tang

    Published 2025-01-01
    “…In particular, the hepatotoxicity associated with statins use has become one of the clinical concerns that require sufficient attention.MethodsIn this study, we conducted a comprehensive and detailed analysis of the hepatotoxicity of statins based on the data of the US Food and Drug Administration Adverse Event Reporting System database from the first quarter (Q1) of 2004 to the Q1 of 2024 and used Reporting Odds Ratios and Empirical Bayes Geometric Mean to mine the signal of adverse events.ResultsIn this study, hepatic disorder related seven statins all exhibited positive signals. …”
    Get full text
    Article
  4. 4

    Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017 by Bao Liu, Xingyue Zhu

    Published 2022-07-01
    “…Objective To explore the associations between the risks of postmarketing safety events of new drugs and the four expedited programmes of priority review, accelerated approval, fast track and breakthrough therapy established by the US Food and Drug Administration (FDA); and to investigate whether multiple uses of expedited programmes, and the combinations of expedited programmes with orphan designation, were relevant to different safety profiles.Design Cohort study.Setting USA.Participants All new drugs approved by the FDA between 1 January 2007 and 31 December 2017, followed up until 10 April 2021.Outcome measures Safety events included safety-related withdrawal, new boxed warning, drug safety communication, postapproval risk evaluation mitigation strategy and safety-related labelling changes. …”
    Get full text
    Article
  5. 5

    Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system by Ashwin Kamath

    Published 2025-01-01
    “…This study aims to conduct an exploratory analysis of the United States Food and Drug Administration adverse event reporting system (FAERS) database to identify previously unknown drugs that can cause EP and supplement the available evidence for known culprit drugs. …”
    Get full text
    Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20